The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access

Takayasu Arteritis: Current Perspective and Brief Narrative Review


Affiliations
1 Undergraduate Student, India
2 Professor and Head, Department of Cardiology, India
3 Professor and Head, Department of Interventional Radiology (Radiodiagnosis), Bharati Vidyapeeth (Deemed to be University) Medical College, Hospital and Research Centre, Pune, Maharashtra, India., India
 

   Subscribe/Renew Journal


Takayasu Arteritis (TA) is a rare chronic inflammatory vascular disorder that mainly causes stenosis and occlusion of large vessels of the body. TA is prevalent in the Asian population with a higher evidence seen in young females. Even though TA has an unclear etiopathogenesis, there are numerous genetic links found associated with TA. Various interventional and radiological investigations prove to be the key for confirming the diagnosis of TA, following which appropriate medical and surgical line of treatment are done, however there is no universal protocol for managing TA. TA has a tendency to progress to serious life threatening complications, hence early diagnosis and treatment should be the goal, also aimed at preventing future re-stenosis, a well-studied complication of TA. It is also crucial to diagnose TA from other overlapping diseases, owing to its peculiar clinical presentation and characteristic radiological findings, which is often confused with other vascular disorders. TA as a disease greatly impacts the quality of life in affected patients with a worse prognosis seen in those who are predisposed to certain well documented risk factors. Furthermore, an increasing number of cases reporting an interesting link between arteritis and the COVID-19 virus have been reported in recent times, which might prove to be crucial in the forthcoming years for establishing this association. Our article aims to sensitize clinicians with regard to an increased awareness of TA in various clinical settings for better patient management and improved prognosis.


Keywords

COVID-19, diagnosis, endovascular, giant cell arteritis, interventions, takayasu arteritis, treatment
Subscription Login to verify subscription
User
Notifications
Font Size


  • Mason JC. Takayasu arteritis--advances in diagnosis and management. Nat Rev Rheumatol. 2010 Jul;6(7):406-15.

  • Numano F. The story of Takayasu arteritis. Rheumatology (Oxford). 2002 Jan;41(1):103-6.

  • Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11.

  • Grayson PC, Maksimowicz-McKinnon K, Clark TM, Tomasson G, Cuthbertson D, Carette S, Khalidi NA, Langford CA, Monach PA, Seo P, Warrington KJ, Ytterberg SR, Hoffman GS, Merkel PA; Vasculitis Clinical Research Consortium. Distribution of arterial lesions in Takayasu’s arteritis and giant cell arteritis. Ann Rheum Dis. 2012 Aug;71(8):1329-34.

  • Yoshida M, Kimura A, Katsuragi K, Numano F, Sasazuki T. DNA typing of HLA-B gene in Takayasu’s arteritis. Tissue Antigens. 1993 Aug;42(2):87-90.

  • Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol. 2002 Jul;55(7):481-6. doi: 10.1136/ jcp.55.7.481.

  • Tripathy NK, Upadhyaya S, Sinha N, Nityanand S.Complement and cell mediated cytotoxicity by antiendothelial cell antibodies in Takayasu’s arteritis. J Rheumatol. 2001 Apr;28(4):805-8.

  • Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu’s arteritis: a 2011 update.Autoimmun Rev. 2011 Nov;11(1):61-7.

  • Gribbons KB, Ponte C, Carette S, Craven A, Cuthbertson D, Hoffman GS, Khalidi NA, Koening CL, Langford CA, Maksimowicz-McKinnon K, McAlear CA, Monach PA, Moreland LW, Pagnoux C, Quinn KA, Robson JC, Seo P, Sreih AG, Suppiah R, Warrington KJ, Ytterberg SR, Luqmani R, Watts R, Merkel PA, Grayson PC. Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. Arthritis Care Res (Hoboken). 2020 Nov;72(11):1615-1624.

  • Watts R, Al-Taiar A, Mooney J, Scott D, Macgregor A. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford). 2009 Aug;48(8):1008-11.

  • Alibaz-Oner F, Direskeneli H. Update on Takayasu’s arteritis. Presse Med. 2015 Jun;44(6 Pt 2):e259-65.

  • Natraj Setty HS, Vijaykumar JR, Nagesh CM, Patil SS, Jadav S, Raghu TR, Manjunath CN. J Rare Dis Res Treat. 2017;2(2): 63-68

  • Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG.Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore). 1985 Mar;64(2):89-99.

  • Dong RP, Kimura A, Numano F, Nishimura Y, Sasazuki T. HLA-linked susceptibility and resistance to Takayasu arteritis. Heart Vessels Suppl. 1992;7:73-80.

  • Kasuya K, Hashimoto Y, Numano F. Left ventricular dysfunction and HLA Bw52 antigen in Takayasu arteritis. Heart Vessels Suppl. 1992;7:116-9.

  • Panja M, Mondal PC. Current status of aortoarteritis in India. J Assoc Physicians India. 2004 Jan;52:48-52.

  • Sen PK, Kinare SG, Enigneer SD, Parulkar GB. The middle aortic syndrome. Br Heart J. 1963 Sep;25(5):610-8.

  • Shimzu K, Sano K. Pulseless disease. J Neuropathol Clin Neurol. 1951 Jan;1(1):37-47.

  • Sharma S, Rajani M, Talwar KK. Angiographic morphology in nonspecific aortoarteritis (Takayasu’s arteritis): a study of 126 patients from north India. Cardiovasc Intervent Radiol. 1992 May-Jun;15(3):160-5. doi: 10.1007/BF02735580.

  • Chhetri MK, Raychaudhuri B, Neelakantan C, Basu J, Chaki S, Saha AK. A profile of non-specific arteritis as observed in Eastern India. J Assoc Physicians India. 1974 Nov;22(11):83947.

  • Sharma BK, Sagar S, Chugh KS, Sakhuja V, Rajachandran A, Malik N. Spectrum of renovascular hypertension in the young in north India: a hospital-based study on occurrence and clinical features. Angiology. 1985 Jun;36(6):370-8.

  • Chugh KS, Jain S, Sakhuja V, Malik N, Gupta A, Gupta A, Sehgal S, Jha V, Gupta KL. Renovascular hypertension due to Takayasu’s arteritis among Indian patients. Q J Med. 1992 Nov-Dec;85(307-308):833-43.

  • Parakh R, Yadav A. Takayasu’s arteritis: an Indian perspective. Eur J VascEndovasc Surg. 2007 May;33(5):578-82.

  • Subramanyan R, Joy J, Balakrishnan KG. Natural history of aortoarteritis (Takayasu’s disease). Circulation. 1989 Sep;80(3):429-37.

  • Sharma BK, Sagar S, Singh AP, Suri S. Takayasu arteritis in India. Heart Vessels Suppl. 1992;7:37-43.

  • Sharma BK, Jain S. A possible role of sex in determining distribution of lesions in Takayasu Arteritis. Int J Cardiol. 1998 Oct 1;66 Suppl 1:S81-4.

  • Keser G, Aksu K, Direskeneli H. Takayasu arteritis: an update. Turk J Med Sci. 2018 Aug 16;48(4):681-697.

  • Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS. Takayasu arteritis. Ann Intern Med. 1994 Jun 1;120(11):919-29.

  • Vanoli M, Daina E, Salvarani C, Sabbadini MG, Rossi C, Bacchiani G, Schieppati A, Baldissera E, Bertolini G; Itaka Study Group. Takayasu’s arteritis: A study of 104 Italian patients. Arthritis Rheum. 2005 Feb 15;53(1):100-7.

  • Ishikawa K. Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu’s arteriopathy. J Am Coll Cardiol. 1988 Oct;12(4):964-72.

  • Ishikawa K. Patterns of symptoms and prognosis in occlusive thromboaortopathy (Takayasu’s disease). J Am Coll Cardiol. 1986 Nov;8(5):1041-6.

  • Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990 Aug;33(8):1129-34.

  • Mavrogeni S, Dimitroulas T, Chatziioannou SN, Kitas G. The role of multimodality imaging in the evaluation of Takayasu arteritis. Semin Arthritis Rheum. 2013 Feb;42(4):401-12.

  • Hartlage GR, Palios J, Barron BJ, Stillman AE, Bossone E, Clements SD, Lerakis S. Multimodality imaging of aortitis. JACC Cardiovasc Imaging. 2014 Jun;7(6):605-19.

  • Schmidt WA. Imaging in vasculitis. Best Pract Res Clin Rheumatol. 2013 Feb;27(1):107-18.

  • Santhosh S, Mittal BR, Gayana S, Bhattacharya A, Sharma A, Jain S. F-18 FDG PET/CT in the evaluation of Takayasu arteritis: an experience from the tropics. J NuclCardiol. 2014 Oct;21(5):993-1000.

  • Keser G, Direskeneli H, Aksu K. Management of Takayasu arteritis: a systematic review. Rheumatology (Oxford). 2014 May;53(5):793-801.

  • Águeda AF, Monti S, Luqmani RA, Buttgereit F, Cid M, Dasgupta B, Dejaco C, Mahr A, Ponte C, Salvarani C, Schmidt W, Hellmich B. Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open. 2019 Sep 23;5(2):e001020.

  • Saadoun D, Lambert M, Mirault T, Resche-Rigon M, Koskas F, Cluzel P, Mignot C, Schoindre Y, Chiche L, Hatron PY, Emmerich J, Cacoub P. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation. 2012 Feb 14;125(6):813-9.

  • Mason JC. Surgical intervention and its role in Takayasu arteritis. Best Pract Res Clin Rheumatol. 2018 Feb;32(1):112-124.

  • Park HS, Do YS, Park KB, Kim DK, Choo SW, Shin SW, Cho SK, Hyun D, Choo IW. Long term results of endovascular treatment in renal arterial stenosis from Takayasu arteritis: angioplasty versus stent placement. Eur J Radiol. 2013 Nov;82(11):1913-8.

  • Jeong HS, Jung JH, Song GG, Choi SJ, Hong SJ. Endovascular balloon angioplasty versus stenting in patients with Takayasu arteritis: A meta-analysis. Medicine (Baltimore). 2017 Jul;96(29):e7558.

  • Park MC, Lee SW, Park YB, Chung NS, Lee SK. Clinical characteristics and outcomes of Takayasu’s arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol. 2005 Jul-Aug;34(4):284-92.

  • Freitas DS, Camargo CZ, Mariz HA, Arraes AE, de Souza AW. Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int. 2012 Mar;32(3):703-9.

  • Liang P, Tan-Ong M, Hoffman GS. Takayasu’s arteritis: vascular interventions and outcomes. J Rheumatol. 2004 Jan; 31(1):102-6.

  • Ishikawa K. Survival and morbidity after diagnosis of occlusive thromboaortopathy (Takayasu’s disease). Am J Cardiol 1981 May;47(5):1026-32.

  • Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu’s disease. Clinical and statistical analyses of related prognostic factors. Circulation. 1994 Oct;90(4):1855-60.

  • Yang L, Zhang H, Jiang X, Zou Y, Qin F, Song L, Guan T, Wu H, Xu L, Liu Y, Zhou X, Bian J, Hui R, Zheng D. Clinical manifestations and longterm outcome for patients with Takayasu arteritis in China. J Rheumatol. 2014 Dec;41(12):2439-46.

  • Maksimowicz-McKinnon K, Clark TM, Hoffman GS.Limitations of therapy and a guarded prognosis in an

  • American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007 Mar;56(3):1000-9.

  • Mehta P, Sattui SE, van der Geest KSM, Brouwer E, Conway R, Putman MS, Robinson PC, Mackie SL. Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. J Rheumatol. 2021 Jul;48(7):1053-1059.

  • Mejren A, Sørensen CM, Gormsen LC, Tougaard RS, Nielsen BD. Large-vessel giant cell arteritis after COVID-19 vaccine.Scand J Rheumatol. 2022 Mar;51(2):154-155.

  • Simão L, Messias A. Giant cell arteritis during COVID-19 pandemic. Arq Bras Oftalmol. 2021 Sep 20;84(5):515-516.

  • Greb CS, Aouhab Z, Sisbarro D, Panah E. A Case of Giant Cell Arteritis Presenting After COVID-19 Vaccination: Is It Just a Coincidence? Cureus. 2022 Jan 25;14(1):e21608.

  • Sauret A, Stievenart J, Smets P, Olagne L, Guelon B, Aumaître O, André M, Trefond L. Case of Giant Cell Arteritis After SARS-CoV-2 Vaccination: A Particular Phenotype? J Rheumatol. 2022 Jan;49(1):120.

  • Tomelleri A, Sartorelli S, Campochiaro C, Baldissera EM, Dagna L. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Ann Rheum Dis. 2020 Sep;79(9):1252-1253.

  • Dhakal P, Khadka S, Clowes JA, Chakinala RC. Aortitis in COVID-19. IDCases. 2021;24:e01063.

  • Riera-Martí N, Romaní J, Calvet J. SARS-CoV-2 infection triggering a giant cell arteritis. Med Clin (Barc). 2021 Mar 12;156(5):253-254.

  • Luther R, Skeoch S, Pauling JD, Curd C, Woodgate F, Tansley S. Increased number of cases of giant cell arteritis and higher rates of ophthalmic involvement during the era of COVID-19. Rheumatol Adv Pract. 2020 Dec 1;4(2):rkaa067.

  • Kramarič J, Ješe R, Tomšič M, Rotar Ž, Hočevar A. COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia. Clin Rheumatol. 2022 Apr 2:1-8.


Abstract Views: 219

PDF Views: 114




  • Takayasu Arteritis: Current Perspective and Brief Narrative Review

Abstract Views: 219  |  PDF Views: 114

Authors

Amanpreet Singh Wasir
Undergraduate Student, India
Ravi Kalra
Professor and Head, Department of Cardiology, India
John D Souza
Professor and Head, Department of Interventional Radiology (Radiodiagnosis), Bharati Vidyapeeth (Deemed to be University) Medical College, Hospital and Research Centre, Pune, Maharashtra, India., India

Abstract


Takayasu Arteritis (TA) is a rare chronic inflammatory vascular disorder that mainly causes stenosis and occlusion of large vessels of the body. TA is prevalent in the Asian population with a higher evidence seen in young females. Even though TA has an unclear etiopathogenesis, there are numerous genetic links found associated with TA. Various interventional and radiological investigations prove to be the key for confirming the diagnosis of TA, following which appropriate medical and surgical line of treatment are done, however there is no universal protocol for managing TA. TA has a tendency to progress to serious life threatening complications, hence early diagnosis and treatment should be the goal, also aimed at preventing future re-stenosis, a well-studied complication of TA. It is also crucial to diagnose TA from other overlapping diseases, owing to its peculiar clinical presentation and characteristic radiological findings, which is often confused with other vascular disorders. TA as a disease greatly impacts the quality of life in affected patients with a worse prognosis seen in those who are predisposed to certain well documented risk factors. Furthermore, an increasing number of cases reporting an interesting link between arteritis and the COVID-19 virus have been reported in recent times, which might prove to be crucial in the forthcoming years for establishing this association. Our article aims to sensitize clinicians with regard to an increased awareness of TA in various clinical settings for better patient management and improved prognosis.


Keywords


COVID-19, diagnosis, endovascular, giant cell arteritis, interventions, takayasu arteritis, treatment

References